Home
Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc. Market Share Analysis for May 2026

Health > Biotechnology and Pharmaceuticals

Domainsyros.com

Year Founded2011

Employees51 - 200

Annual Revenue$15M - $25M

Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc. (including company regionals)

syros.com

See more website traffic and engagement information

Syros Pharmaceuticals, Inc. Revenue up to May 2026 is 15M - 25M

revenue generated by Syros Pharmaceuticals, Inc. top domains

Syros Pharmaceuticals, Inc. top domains revenue over 3 years

Revenue for Syros Pharmaceuticals, Inc. top domains

syros.com15M - 25M

See more with Sales Intelligence

Total visits to Syros Pharmaceuticals, Inc.'s top domains

Understand Syros Pharmaceuticals, Inc. market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Syros Pharmaceuticals, Inc.'s top domains

Analyze Syros Pharmaceuticals, Inc. engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Syros Pharmaceuticals, Inc.'s top domains

See how Syros Pharmaceuticals, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Syros Pharmaceuticals, Inc. top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Syros Pharmaceuticals, Inc.

These are the website technologies, by industry, used by Syros Pharmaceuticals, Inc. top domains

Content Management System (4)

Squarespace

Audio Video Media (2)

Facebook Video

Marketing (2)

Google Marketing Platform

Mobile (2)

Meta Viewport

More Technologies

9

See all

News & Signals from Syros Pharmaceuticals, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsSyros Pharmaceuticals partnered with Oxford Finance LLC on Feb 28th '25.In response to these issues, Syros Pharmaceuticals has secured a forbearance agreement with Oxford Finance after defaulting on a loan, with a resolution aimed for by the end of February 2025.

NewsSyros Pharmaceuticals has issues with violations of the securities laws.LOS ANGELES-(BUSINESS WIRE)-The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ: SYRS) for violations of the securities laws.

NewsSyros Pharmaceuticals hired Nancy Simonian as CEO on Dec 2nd '23.Also today, Syros announced the retirement as Chief Executive Officer (CEO) of Nancy Simonian, M.D., and the appointment of Conley Chee, Syros' Chief Commercial Officer (CCO) and Chief Business Officer (CBO), as CEO, effective December 2, 2023.